Investigating a new target for treating pulmonary fibrosis
Official title: Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis
Funded at Methodist Hospital Research Institute · NIH-11056446 · Data updated 2026-11-12
This study is looking at a protein called Cdk9 to see how it affects lung inflammation and scarring in people with idiopathic pulmonary fibrosis (IPF), with the goal of finding new treatments that can help manage the disease better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Methodist Hospital Research Institute NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 1, 2025 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $705,334 |
| NIH project number | 1R01HL177797-01 |
| Project ID | NIH-11056446 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
✕Less likely to help
Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on understanding the role of cyclin-dependent kinase 9 (Cdk9) in the development of idiopathic pulmonary fibrosis (IPF), a serious lung disease. The researchers aim to identify new drug targets that can improve treatment strategies for IPF, which currently has limited effective therapies. By studying how Cdk9 influences inflammation and fibrosis in lung cells, they hope to develop new medications that can better manage the disease and improve patient outcomes. The approach includes using Cdk9 inhibitors in laboratory models to assess their effectiveness in reducing lung fibrosis and enhancing survival.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with idiopathic pulmonary fibrosis, potentially improving their quality of life and survival rates.
How similar studies have gone: Previous research has shown promise in targeting similar pathways for treating fibrotic diseases, suggesting that this approach may yield beneficial results.
Where this research is happening
-
Methodist Hospital Research Institute
Houston, United States Active
Researchers
- Principal investigator: Haudenschild, Dominik R — Methodist Hospital Research Institute
- Study coordinator: Haudenschild, Dominik R
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.